Özet:

Objective: To determine the benefits of the combination of bacillus Calmette-Guerin (BCG) and mitomycin C (MMC) in comparison to BCG alone in the treatment of patients with non-muscle invasive (NMI) bladder cancer. Materials and Methods: The randomized comparative study was conducted on 54 patients with NMI bladder cancer. Following the transurethral resection, patients were randomly grouped into two: Group A (n=27) included patients who received postoperative MMC at 40 mg diluted in 50 mL of normal saline on postoperative day 1, followed by intravesical BCG at 60 mg per week for 6 weeks and BCG monthly for 1 year, and group B (n=27) included patients who received intravesical BCG at 60 mg postoperatively per week for 6 weeks followed by BCG monthly for 1 year. The outcome measures were time to recurrence, progression of the disease to muscles or other organs, overall survival, and treatment-related side effects. Results: Compared to BCG alone, perioperative MMC in combination with BCG had comparable disease-free survival (85.18% vs. 66.66%, p=0.202), recurrence of disease (14.81% vs. 33.33%, p=0.202), and progression rate (11.1% vs. 25.9%, p=0.293). Side effects were minor and comparable between the study groups, which included dysuria, bacterial cystitis drug-induced cystitis, macroscopic hematuria prostatitis epididymitis fever, influenza-like symptoms, and fatigue. Conclusion: Overall, both protocols were found comparable in safety and efficacy in reducing the progression and recurrence of NMI bladder cancers without any significant superiority of MMC in combination with BCG in comparison to BCG alone.

Anahtar Kelimeler: